MarketInOut Stock Screener Log In | Sign Up
 

Catalyst Pharmaceuticals Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 05/04/2026 16:00
Catalyst Pharmaceuticals Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,509.84 mln
Float115 mln
Earnings Date05/13/2026

EPS

1.68
Moderate

P / E

17.23
Moderately valued

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-1.79
Caution advised

1-Year Forecast

34.14
Attractive

Relative Strength

92 / 100
Top performer

Business Description

Catalyst Pharmaceuticals is a Florida-based company that develops and sells treatments for patients with rare and serious medical conditions. Its current portfolio includes three approved medicines targeting nerve and muscle disorders, including Lambert-Eaton myasthenic syndrome, certain types of epilepsy, and Duchenne muscular dystrophy. The company also works with outside partners to expand its reach through licensing and development agreements.

Key Fundamentals

EPS1.68
P/E17.23
ROE25.20
RPS4.63
ROIC81.16
ROA21.92
EBITDA, mln296
EV / EBITDA9.70
EV / EBIT11.13
Revenue, mln589
EV / Revenue4.87

Financial Strength

Altman Z-Score16.19
Piotroski F-Score 4 / 9
Beneish M-Score-1.79
Price to Intrinsic Value1.45
Price to Lynch Fair Value0.58
Price to Graham Number1.67
1-Year Target Price34.14
Shiller PE Ratio55.27
Short Ratio7.17
Short % of Float8.89

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.13% 28 / 100   
1 Month 17.21% 84 / 100   
2 Months 20.63% 89 / 100   
6 Months 38.01% 90 / 100   
1 Year 19.24% 59 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us